immatics is developing new cancer drugs that help to activate specialized white blood cells of the patient’s immune system against cancer cells.
This page contains information about clinical trials sponsored by immatics or performed in collaboration with immatics and is provided for patients and healthcare professionals to increase the transparency of immatics' clinical product pipeline.
Information contained within this website is not intended to replace any advice from a healthcare professional and must not be considered as a treatment recommendation. Patients should always seek professional and qualified medical advice before making any decisions on their treatment.
All reasonable precautions have been taken to ensure the accuracy of the information available through the site. immatics may amend the information at any time without notice.
|
Drug |
Peptide-based renal cell cancer vaccine IMA901 |
|
Sponsor |
immatics biotechnologies GmbH |
|
Study code |
IMA901-301 (phase III study) |
|
Status |
Recruitment completed |
|
Objective |
Prolongation of survival in patients with advanced renal cell cancer (RCC) |
|
Participating countries |
France, Germany, Hungary, Italy, Poland, Rumania, Russia, UK, USA, Netherlands, Norway |
|
Information |
-/ clinicaltrials.gov
|
|
Drug |
Peptide-based glioma vaccine IMA950 |
|
Sponsor |
Cancer Research UK |
|
Study code |
CR0902-11 (phase I study) |
|
Status |
Recruitment completed |
|
Objective |
Evaluation of safety and immunological activity |
|
Participating countries |
United Kingdom |
|
Information |
|
Drug |
Peptide-based glioma vaccine IMA950 |
|
Sponsor |
immatics biotechnologies GmbH |
|
Study code |
IMA950-102 (phase I study) |
|
Status |
Recruiting |
|
Objective |
Evaluation of safety and immunological activity |
|
Participating countries |
United States of America (National Cancer Institute, Bethesda, MD) |
|
Information |